Dr. Rebecca L Aft, M.D., Ph.D.
Claim this profileWashington University School of Medicine
Studies Breast Cancer
Studies Vulval Intraepithelial Neoplasia
10 reported clinical trials
25 drugs studied
Area of expertise
1Breast Cancer
HER2 negative
Stage II
ER positive
2Vulval Intraepithelial Neoplasia
Stage I
Stage II
Affiliated Hospitals
Clinical Trials Rebecca L Aft, M.D., Ph.D. is currently running
SRG-514
for Breast Cancer
This is a multicenter, first-in-human (FIH), open label, Phase 1 dose escalation and recommended Phase 2 dose (RP2D) extension trial with a primary objective to define the RP2D of SRG-514 when administered intraoperatively to patients undergoing breast-conserving cancer surgery. SRG-514 will be investigated utilizing a 3+3 convention dose escalation cohorts.
Recruiting1 award Phase 13 criteria
Fluorescence Imaging
for Breast Cancer Surgery
The investigators' preclinical data have demonstrated the feasibility of fluorescence-guided tumor resection by Cancer Vision Goggles (CVG) with LS301 in animal models. In this study, the investigators will conduct intraoperative imaging procedures that have minimal interference with ongoing surgery. The underlying hypothesis is that the accurate detection of all cancer cells highlighted by LS301 during surgery will reduce the number of breast cancer patients with margin positivity to less than 5%, compared to the current surgical paradigm of greater than 20%. The pilot study will obtain critical data required to address the larger question of surgical margin assessment in a full Phase I clinical trial. Phase 1: to determine the safety and optimal imaging dose of LS301 injected in breast cancer patients. Phase 2: to determine the ability of this novel fluorescence imaging agent to predict the presence of positive margins around partial mastectomy specimens and positive SLNs during surgical therapy for breast cancer.
Recruiting1 award Phase 1 & 24 criteria
More about Rebecca L Aft, M.D., Ph.D.
Clinical Trial Related1 year of experience running clinical trials · Led 10 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Rebecca L Aft, M.D., Ph.D. has experience with
- Anastrozole
- Exemestane
- Fulvestrant
- Goserelin
- Tamoxifen
- LS301
Breakdown of trials Rebecca L Aft, M.D., Ph.D. has run
Breast Cancer
Vulval Intraepithelial Neoplasia
Ductal Carcinoma
Lobular Carcinoma in Situ
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Rebecca L Aft, M.D., Ph.D. specialize in?
Rebecca L Aft, M.D., Ph.D. focuses on Breast Cancer and Vulval Intraepithelial Neoplasia. In particular, much of their work with Breast Cancer has involved HER2 negative patients, or patients who are Stage II.
Is Rebecca L Aft, M.D., Ph.D. currently recruiting for clinical trials?
Yes, Rebecca L Aft, M.D., Ph.D. is currently recruiting for 4 clinical trials in Saint Louis Missouri. If you're interested in participating, you should apply.
Are there any treatments that Rebecca L Aft, M.D., Ph.D. has studied deeply?
Yes, Rebecca L Aft, M.D., Ph.D. has studied treatments such as Anastrozole, Exemestane, Fulvestrant.
What is the best way to schedule an appointment with Rebecca L Aft, M.D., Ph.D.?
Apply for one of the trials that Rebecca L Aft, M.D., Ph.D. is conducting.
What is the office address of Rebecca L Aft, M.D., Ph.D.?
The office of Rebecca L Aft, M.D., Ph.D. is located at: Washington University School of Medicine, Saint Louis, Missouri 63110 United States. This is the address for their practice at the Washington University School of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.